Synthesis and In vitro P-Glycoprotein Inhibitory Activity of Novel 1,4-Dihydropyridine Derivatives
DOI:
https://doi.org/10.37285/ijpsn.2014.7.3.6Abstract
Two series of new symmetrical 4-aryl-2,6-dimethyl-3,5-bis-N-(aryl/heteroaryl)-carbamoyl-1,4-dihydropyridines (4a-f) and asymmetrical 4-aryl-2,6-dimethyl-3-N-(aryl/hetero-aryl)-carbamoyl-5-ethyl carboxylate-1,4-dihydro-pyridines (5a-f) have been synthesized by simple, economical and eco-friendly, modified Hantzsch reaction using N-aryl/heteroarylacetoacetamides (3a-c), ethylaceto-acetate (for asymmetric), arylaldehydes and urea in presence of catalytic amounts of LiBr/Iodine and by microwave irradiation methods. The newly synthesized compounds were characterized by physical and spectral data, and evaluated for their possible in vitro MDR reversal activity by everted sac method using verapamil as standard P-gp inhibitor and domperidone as the standard P-gp substrate. Amongst the compounds tested, compound 4f exhibited the highest in vitro P-gp inhibitory activity. It was found to be more potent than the standard verapamil.
Downloads
Metrics
Keywords:
Multidrug resistance, P-gp, Asymmetric and symmetric 1,4-dihydropyridines, Everted sac method, N-aryl/heteroarylacetoacetamide
Downloads
Published
How to Cite
Issue
Section
References
Akbari JD, Tala SD, Dhaduk MF, Joshi HS (2008). Molecular iodine-catalyzed one-pot synthesis of some new Hantzsch 1,4-dihydropyridines at ambient temperature. ARKIVOC 12: 126-135.
Choi CH (2005). ABC transporters as MDR mechanisms and development of chemosensitizers for their reversal. Cancer Cell Int 5: 30-42.
Gottesman MM (1993). How cancer cells evade chemotherapy. Cancer Res 53(4): 747-754.
Harold M (2002). Angiotensin converting enzyme inhibitors, antagonists and calcium channel blockers. In: Lemke TL, Williams DA editors. Foye’s Principles of Medicinal Chemistry. 5th ed. Lippincott Williams and Wilkins; pp. 533-561.
Hesson C, Seo-Young J (2005). P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient. European Patent EP1545495 A1.
Kawase M, Shah A, Gaveriya H, Motohashi N, Sakagami H, Varga A, Molnar J (2002). 3,5-dibenzoyl-1,4-dihydropyridines-synthesis and MDR reversal in tumor cells. Bioorg Med Chem 10(4): 1051-1055.
Khoshneviszadeh M, Edraki N, Javidnia K, Alborzi A, Pourabass B, Mardaneh J, Miri R (2009). Synthesis and biological evaluation of some new 1,4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents. Bioorg Med Chem 17: 1579-1586.
Kumar RS, Idhayadhulla A, Abdul Nasser AJ, Kavimani S, Indumathy S (2010). Synthesis and anticonvulsant activity of a new series of 1,4-dihydropyridine derivatives. Ind J Pharm Sci 72(6): 719-725.
Miri R, Javidnia K, Sarkarzadeh H, Henmateenejad B (2006). Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonists. Bioorg Med Chem 14(14): 4842-4849.
Morrow CS, Cowan KH (1997). Drug resistance and its clinical circumvention. In: Holland JJ, Frei E, Bast JC, Kufe DW, Morton DL, Weichselbaum RR editors. Cancer Medicine. 4th ed. Williams and Wilkins; pp. 799-815.
Philip AA, Joel S, Monkman SC, Dolega-Ossowski E, Tonkin K, Carmichael J, Idle JR, Harris AL (1992). A phase I study on the reversal of MDR in vivo: nifedipine plus etoposide. Br J Cancer 65(2): 267-270.
Shrikanth U, Santhosh K, Ramakrishna S, Airody Vasudeva A (2013). New dihydropyridine derivatives: anti-inflammatory, analgesic and docking studies. Med Chem Res 22(4): 1549-1562.
Sirisha K, Achaiah G, Reddy VM (2010). Facile Synthesis and Antibacterial, Antitubercular, and Anticancer Activities of Novel 1,4-Dihydropyridines. Arch Pharm Chem Life Sci 343: 342-352.
Sirisha K, Chandrasekhar M, Umasankar K, Mahendar P, Sadanandam A, Achaiah G, Reddy VM (2011). Molecular docking studies and in vitro screening of new dihydropyridine derivatives as human MRP1 inhibitors. Bioorg Med Chem 19: 3249-3254.
Sirisha K, Bikshapathi G, Achaiah G, Reddy VM (2011). Synthesis, antibacterial and antimycobacterial activities of some new 4-aryl/heteroaryl-2,6-dimethyl-3,5-bis-N-(aryl)-carbamoyl-1,4-dihydropyridines. Eur J Med Chem 46: 1564-1571.
Sirisha K, Rajyalaxmi I, Olivia S (2013). Process optimization and eco-friendly/greener synthesis of some n-aryl/heteryl-acetoacetamides. Int Curr Pharmaceut J 2(11): 189-192.
Varma MV, Ashokraj Y, Dey CS, Panchagnula R (2003). P-glycoprotein inhibitor and their screening: a perspective from bioavailability enhancement. Pharmacol Res 48(4): 347-359.
Walash MI, Belal F, EI-Enany N, Abdelal AA (2008). Second-derivative synchronous fluorescence spectroscopy for the simultaneous determination of cinnarizine and domperidone in pharmaceutical preparations. Applications to biological fluids. JFluoresc 18: 61-74.
Yadav DK, Patel R, Srivastava VP, Watal G, Yadav LDS (2011). LiBr as an Efficient Catalyst for One-pot Synthesis of Hantzsch 1,4-Dihydropyridines under Mild Conditions. Chin J Chem 29: 118-122.
Zarrin A, Mehdipour AR, Miri R (2010). Dihydropyridines and multidrug resistance: previous attempts, present state, and future trends. Chem Biol Drug Des 76(5): 369-381.
Zhou XF, Zhang L, Tseng E, Scott-Ramsay E, Schentag JJ, Coburn RA, Morris ME (2005). New 4-aryl-1,4-dihydropyridines and 4-aryl pyridines as P-gp inhibitors. Drug Metab Dispos 33(8): 321-328.
